W5701

W5701 is a small molecule drug candidate being developed by Shanghai Pharmaceuticals Holding Co., Ltd for the treatment of metabolic diseases. As of early 2024, the candidate is in the Investigational New Drug (IND) stage of development, representing a part of the company's expanding portfolio in the digestive and metabolic therapeutic areas. While the specific biological target has not been publicly disclosed in high-level pipeline summaries, W5701 is classified as a Class 1 new drug in China, indicating it is a new chemical entity. The "W" prefix in its code name is characteristic of several candidates in the Shanghai Pharma pipeline, often associated with specific internal or collaborative discovery programs.